Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Accounts Payables: 2024-2025

Historic Accounts Payables for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $66.8 million.

  • Kura Oncology's Accounts Payables rose 80.67% to $66.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.8 million, marking a year-over-year increase of 80.67%. This contributed to the annual value of $50.0 million for FY2024, which is N/A change from last year.
  • Per Kura Oncology's latest filing, its Accounts Payables stood at $66.8 million for Q3 2025, which was up 26.18% from $52.9 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Accounts Payables registered a high of $66.8 million during Q3 2025, and its lowest value of $30.9 million during Q1 2024.
  • For the 2-year period, Kura Oncology's Accounts Payables averaged around $44.8 million, with its median value being $45.1 million (2025).
  • Data for Kura Oncology's Accounts Payables shows a peak YoY soared of 80.67% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Kura Oncology's Accounts Payables stood at $50.0 million in 2024, then spiked by 80.67% to $66.8 million in 2025.
  • Its Accounts Payables stands at $66.8 million for Q3 2025, versus $52.9 million for Q2 2025 and $45.1 million for Q1 2025.